252 related articles for article (PubMed ID: 23393117)
1. Drug companies will have to report all payments to US doctors from March 2014.
Roehr B
BMJ; 2013 Feb; 346():f826. PubMed ID: 23393117
[No Abstract] [Full Text] [Related]
2. Sunlight as disinfectant--new rules on disclosure of industry payments to physicians.
Rosenthal MB; Mello MM
N Engl J Med; 2013 May; 368(22):2052-4. PubMed ID: 23718162
[No Abstract] [Full Text] [Related]
3. The Sunshine Act--effects on physicians.
Agrawal S; Brennan N; Budetti P
N Engl J Med; 2013 May; 368(22):2054-7. PubMed ID: 23718163
[No Abstract] [Full Text] [Related]
4. The Sunshine Act: it's for real now.
Katayama AC
WMJ; 2013 Apr; 112(2):96-7. PubMed ID: 23758019
[No Abstract] [Full Text] [Related]
5. Open Payments Program (aka the Sunshine Act) makes public debut.
Schmidt C
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214569
[No Abstract] [Full Text] [Related]
6. Industry paid $6.5 bn to US physicians and hospitals in 2014.
McCarthy M
BMJ; 2015 Jul; 350():h3697. PubMed ID: 26152208
[No Abstract] [Full Text] [Related]
7. New US law applies 'sunshine' to physician payments and gifts from drug, device industries.
Woodward C
CMAJ; 2010 Jul; 182(10):E467-8. PubMed ID: 20501787
[No Abstract] [Full Text] [Related]
8. Doctors and drug companies--scrutinizing influential relationships.
Campbell EG
N Engl J Med; 2007 Nov; 357(18):1796-7. PubMed ID: 17978288
[No Abstract] [Full Text] [Related]
9. Physician payment sunshine act.
Merino JG
BMJ; 2013 Aug; 347():f4828. PubMed ID: 23908473
[No Abstract] [Full Text] [Related]
10. Health policy basics: the Physician Payment Sunshine Act and the Open Payments program.
Kirschner NM; Sulmasy LS; Kesselheim AS
Ann Intern Med; 2014 Oct; 161(7):519-21. PubMed ID: 25069795
[TBL] [Abstract][Full Text] [Related]
11. "Transparency reports" on industry payments to physicians and teaching hospitals.
Steinbrook R; Ross JS
JAMA; 2012 Mar; 307(10):1029-30. PubMed ID: 22336624
[No Abstract] [Full Text] [Related]
12. US doctors earn speaking and consulting fees from drug companies that sponsor their research.
McCarthy M
BMJ; 2014 Mar; 348():g2410. PubMed ID: 24677695
[No Abstract] [Full Text] [Related]
13. Industry spending on continuing medical education in US falls further.
Roehr B
BMJ; 2012 Aug; 345():e5336. PubMed ID: 22872716
[No Abstract] [Full Text] [Related]
14. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement.
Moynihan R
BMJ; 2003 May; 326(7400):1193-6. PubMed ID: 12775622
[No Abstract] [Full Text] [Related]
15. Already feeling the heat: Docs rethinking payments as Sunshine Act looms.
Lee J
Mod Healthc; 2013 Jul; 43(26):12-3. PubMed ID: 23878901
[No Abstract] [Full Text] [Related]
16. Disclosure of industry payments to physicians.
Steinbrook R
N Engl J Med; 2008 Aug; 359(6):559-61. PubMed ID: 18687636
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: business practices. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840
[No Abstract] [Full Text] [Related]
18. Drug companies, doctors and disclosures.
Tuorto S; Chan MK; Adusumilli PS
Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772
[No Abstract] [Full Text] [Related]
19. Transparency of industry payments needed in clinical practice guidelines.
Vassar M; Bibens M; Wayant C
BMJ Evid Based Med; 2019 Feb; 24(1):8-9. PubMed ID: 30042209
[No Abstract] [Full Text] [Related]
20. GlaxoSmithKline to limit payments it makes to US doctors to $150,000 a year.
Kmietowicz Z
BMJ; 2008 Oct; 337():a2315. PubMed ID: 18974258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
